[
  {
    "id": "note-0",
    "title": "Welcome to OME Medicine Notes",
    "path": "Welcome.md",
    "content": "\n  welcome to ome medicine notes\n\nthis is a sample vault to demonstrate the   obsidian publisher   features.\n\n   features demonstrated\n\n-   heart failure   - a complete cardiology note\n-   asthma   - a pulmonology note with callouts\n- wikilinks and navigation\n- full-text search (try searching for \"bnp\" or \"albuterol\")\n- dark/light mode toggle\n- export to pdf or markdown\n\n   quick stats\n\n| specialty | notes count |\n|-----------|-------------|\n| cardiology | 1 |\n| pulmonology | 1 |\n\n   tags\n\ncheck out notes tagged with  cardiology or  pulmonology.\n\n---\n\n>  !tip \n> use the sidebar to navigate through the folder structure, or use   cmd/ctrl + k   to search!\n"
  },
  {
    "id": "note-1",
    "title": "Asthma",
    "path": "Pulmonology/Asthma.md",
    "content": "\n  asthma\n\nasthma is a chronic inflammatory disorder of the airways characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness, and underlying inflammation.\n\n   pathophysiology\n\nthe key features are:\n\n1.   chronic airway inflammation   - eosinophils, mast cells, t-lymphocytes\n2.   bronchial hyperreactivity   - exaggerated bronchoconstriction\n3.   reversible airflow obstruction   - responds to bronchodilators\n\n   clinical features\n\n    symptoms\n- wheezing (expiratory)\n- shortness of breath\n- chest tightness\n- cough (often nocturnal)\n\n>  !tip \n> symptoms often worse at night or early morning, and triggered by:\n> - allergens (dust, pollen, pets)\n> - exercise\n> - cold air\n> - respiratory infections\n\n    physical exam\n- wheezing on auscultation\n- prolonged expiratory phase\n- use of accessory muscles (severe)\n- nasal polyps (in aspirin-exacerbated disease)\n\n   diagnosis\n\n    spirometry (key test)\n| parameter | findings |\n|-----------|----------|\n| fev1 | reduced |\n| fvc | normal or reduced |\n| fev1/fvc | <0.70 (obstructive pattern) |\n| bronchodilator response | ≥12% and ≥200ml improvement |\n\n    other tests\n- peak flow variability >20%\n- methacholine challenge (if spirometry normal)\n- exhaled nitric oxide (feno) - elevated in eosinophilic asthma\n- allergy testing\n\n   classification by severity\n\n   \nintermittent:\n  - symptoms ≤2 days/week\n  - night symptoms ≤2x/month\n  - fev1 ≥80% predicted\n\nmild persistent:\n  - symptoms >2 days/week (not daily)\n  - night symptoms 3-4x/month\n  - fev1 ≥80% predicted\n\nmoderate persistent:\n  - daily symptoms\n  - night symptoms >1x/week\n  - fev1 60-80% predicted\n\nsevere persistent:\n  - continuous symptoms\n  - frequent night symptoms\n  - fev1 <60% predicted\n   \n\n   treatment\n\n    quick-relief medications\n\n>  !important \n>   saba   (short-acting beta-agonist) is the first-line rescue medication\n> - albuterol (salbutamol)\n> - levalbuterol\n\n    controller medications (stepwise approach)\n\n  step 1  : saba as needed\n  step 2  : low-dose ics\n  step 3  : low-dose ics + laba\n  step 4  : medium-dose ics + laba\n  step 5  : high-dose ics + laba ± add-on therapy\n  step 6  : oral corticosteroids + biologics\n\n    biologics for severe asthma\n-   omalizumab   - anti-ige (allergic asthma)\n-   mepolizumab/benralizumab   - anti-il-5 (eosinophilic)\n-   dupilumab   - anti-il-4/13\n\n   acute exacerbation management\n\n>  !caution \n> signs of life-threatening asthma:\n> - silent chest\n> - cyanosis\n> - altered consciousness\n> - spo2 <92%\n\nmanagement algorithm:\n1.   oxygen   - target spo2 94-98%\n2.   saba nebulizer   - q20min x3, then as needed\n3.   ipratropium   - add in severe exacerbations\n4.   corticosteroids   - prednisone 40-60mg po (or iv methylpred)\n5.   consider  : magnesium sulfate iv, epinephrine\n\n   related notes\n- back to:   heart failure   for cardiac causes of dyspnea\n-   welcome   for vault overview\n\n---\n\n pulmonology  asthma  chronic\n"
  },
  {
    "id": "note-2",
    "title": "Heart Failure",
    "path": "Cardiology/Heart Failure.md",
    "content": "\n  heart failure\n\nheart failure (hf) is a clinical syndrome caused by structural or functional cardiac abnormalities resulting in reduced cardiac output and/or elevated intracardiac pressures.\n\n   classification\n\n    by ejection fraction\n-   hfref   (reduced ef): ef ≤40%\n-   hfmref   (mildly reduced ef): ef 41-49%\n-   hfpef   (preserved ef): ef ≥50%\n\n    by timing\n-   acute hf  : rapid onset of symptoms\n-   chronic hf  : progressive, long-term condition\n\n   etiology\n\n1.   ischemic heart disease   (most common)\n2. hypertension\n3. valvular disease\n4. cardiomyopathies\n5. arrhythmias\n\n   clinical features\n\n>  !important \n> remember the classic presentation:\n> -   left-sided failure  : dyspnea, orthopnea, pnd, pulmonary edema\n> -   right-sided failure  : jvd, peripheral edema, hepatomegaly\n\n    symptoms\n- dyspnea on exertion\n- orthopnea (need to sleep with pillows)\n- paroxysmal nocturnal dyspnea (pnd)\n- fatigue\n- lower extremity edema\n\n    signs\n- elevated jvp\n- s3 gallop (volume overload)\n- pulmonary crackles\n- peripheral edema\n- hepatomegaly\n\n   diagnosis\n\n    labs\n| test | finding in hf |\n|------|---------------|\n| bnp | >100 pg/ml suggests hf |\n| nt-probnp | >300 pg/ml in acute setting |\n| troponin | may be elevated in acute hf |\n\n    imaging\n-   echocardiogram  : gold standard for ef assessment\n-   cxr  : cardiomegaly, pulmonary congestion\n-   cardiac mri  : for detailed structural assessment\n\n   treatment\n\n    acute management\n   \n1. position: sit patient upright\n2. oxygen: target spo2 ≥94%\n3. diuretics: iv furosemide 40-80mg\n4. vasodilators: nitrates if bp adequate\n5. consider: inotropes if cardiogenic shock\n   \n\n    chronic hfref (four pillars of therapy)\n\n>  !note \n> guideline-directed medical therapy (gdmt) includes four classes of drugs that reduce mortality:\n\n1.   ace inhibitor/arb/arni   - start low, titrate up\n2.   beta-blocker   (carvedilol, metoprolol succinate, bisoprolol)\n3.   mineralocorticoid receptor antagonist   (spironolactone, eplerenone)\n4.   sglt2 inhibitor   (dapagliflozin, empagliflozin)\n\n    device therapy\n-   icd  : for ef ≤35% after 3 months of gdmt\n-   crt  : for ef ≤35% + lbbb + qrs ≥150ms\n\n   prognosis\n\n>  !warning \n> 5-year mortality is approximately 50% after diagnosis. early gdmt initiation is crucial!\n\n   related notes\n- see also:   asthma   for pulmonary differential\n\n---\n\n cardiology  hf  acute\n"
  }
]